All In Biotech

Drug Trial Radar · NCT02760368

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy

Last checked: Nov 20, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 428 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

428

Actual

Start

May 19, 2016

Primary completion

Aug 2018

Study completion Oct 2018

Sponsor

Lead sponsor
R-Pharm International, LLCIndustry
Sponsor type
Industry
Collaborators
Quintiles, Inc.; OCT Clinical Trials; Mene Research
First posted
May 3, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with methotrexate (MTX). The primary objective of this study was to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active rheumatoid arthritis (RA) inadequately controlled by methotrexate (MTX) therapy.

Conditions

  • Rheumatoid Arthritis

Interventions

  • OlokizumabDrug

    160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial

  • PlaceboDrug

    sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) ResponseTime frame: at Week 12

Locations

40 sites in 3 countries. Site status is shown where the registry gives one.

  • City Clinical Hospital #1

    Minsk, Belarus

  • Vitebsk Regional Clinical Hospital

    Vitebsk, Belarus

  • DCC 'Sv. Pantaleymon' OOD

    Pleven, Bulgaria

  • UMHAT "Kaspela", EOOD

    Plovdiv, Bulgaria

  • UMHAT "Sv. Ivan Rilski", EAD

    Sofia, Bulgaria

  • MC "Synexus - Sofia", EOOD

    Sofia, Bulgaria

  • FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova"

    Moscow, Russia

  • City Clinical Hospital №5 of Nizhny Novgorod

    Nizhny Novgorod, Russia

  • Ryazan State Medical University n.a. I.P. Pavlov based on Regional Clinical Cardiology Dispensary

    Ryazan, Russia

  • SBHI "North-West Federat Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation

    Saint Petersburg, Russia

  • Regional State Budgetary Healthcare Institution "Barnaul City Hospital #4"

    Barnaul, Altayskiy Kray, Russia

  • SAHI of Kemerovo region "Regional Clinical Hospital for War Veterans"

    Kemerovo, Kemerovo Oblast, Russia

  • Medical Center LLC "Maksimum Zdoroviya"

    Kemerovo, Kemerovo Oblast, Russia

  • Budgetary Healthcare Institution "Kursk Regional Clinical Hospital" of Healthcare Committee of Kursk region

    Kursk, Kursk Oblast, Russia

  • SPb SBHI "Clinical Rheumatological Hospital #25", Fourth Rheumatology Unit

    Saint Petersburg, Leningradskaya Oblast', Russia

  • FSBEI HE "First Moscow State Medical University n.a. I.M. Sechenov of MoH of Russian Federation", UCH #1

    Moscow, Moscovskaya Oblast, Russia

  • FSBEI HE "FMSMU n.a. I.M. Sechenov of MoH of RF", University Hospital #2, Departament of New Drugs Introduction

    Moscow, Moscovskaya Oblast, Russia

  • SBEI HPE "First Moscow State Medical University n.a. I.M. Sechenov of MoH of Russian Federation" UCH #3

    Moscow, Moscovskaya Oblast, Russia

  • State Budgetary Healthcare Institution of Moscow "City Clinical Hospital #1 n.a. Pirogov" Healthcare Departament of Moscow

    Moscow, Moscovskaya Oblast, Russia

  • State Budgetary Healthcare Institution "City Clinical Hospital # 15 n.a O.M. Filatov" of Moscow Healtheare Department

    Moscow, Moscow Oblast, Russia

  • SBHI of Moscow "City Clinical Hospital #4 of Moscow Healthcare Departament"

    Moscow, Moscow Oblast, Russia

  • SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a.Semashko"

    Nizhny Novgorod, Nizhny Novgorod Oblast, Russia

  • State Autonomous Healthcare Institution of Novosibirsk region "City Polyclinic #1"

    Novosibirsk, Novosibirsk Oblast, Russia

  • LLC "Clinical Diagnostic Center "Ultramed"

    Omsk, Omsk Oblast, Russia

  • Budgetary Healthcare Institution of Omsk Region "Regional Clinical Hospital"

    Omsk, Omsk Oblast, Russia

  • SBHI of the Republic of Karelia "Republican Hospital named after V.A. Baranov"

    Petrozavodsk, Republic of Karelia, Russia

  • State Budgetary Healthcare Institution "Republican Clinical Hospital n.a. G.G. Kuvatov"

    Ufa, Respublic of Bashkortostan, Russia

  • SBEI HPE "Rostov State Medical University" of Ministry of Health of the Russian Federation

    Rostov-on-Don, Rostov Oblast, Russia

  • State Healthcare Institution "Regional Clinical Hospital"

    Saratov, Saratov Oblast, Russia

  • SBEI HPE "SSMU n.a. V.I. Razumovsky of MoH of RF", Clinical Hospital n.a. S.R. Mirotvorcev, Therapeutic Departament

    Saratov, Saratov Oblast, Russia

  • Non-governmental Healtheare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways"

    Smolensk, Smolensk Oblast, Russia

  • SBHI of Stavropol Region "Stavropol Regional Clinical Hospital"

    Stavropol, Stavropol Kray, Russia

  • State Budgetary Healthcare Institution of Sverdlovsk Region "Sverdlovsk Regional Clinical Hospital #1"

    Yekaterinburg, Sverdlovsk Oblast, Russia

  • SBEI HPE "Ural State Medical University" of MoH of RF based MBI "Central City Clinical Hospital #6"

    Yekaterinburg, Sverdlovsk Oblast, Russia

  • State Autonomous Healthcare Institution "Republican Clinical Hospital of Ministry of Health of Tatarstan Republic

    Kazan', The Republic of Tatarstan, Russia

  • State Healthcare Institution of Tula region "Tula Regional Clinical Hospital"

    Tula, Tulskaya Oblast, Russia

  • State Healthcare Institution "Ulyanovsk Regional Clinical Hospital"

    Ulyanovsk, Ulyanovsk Oblast, Russia

  • SBHI of Vladimir Region "Regional Clinical Hospital", Rheumatology Departament

    Vladimir, Vladimirskaya Oblast’, Russia

  • SBHI "Yaroslavl Regional Clinical Hospital", Rheumatology department

    Yaroslavl, Yaroslavl Oblast, Russia

  • State Autonomous Helthcare Institution of Yaroslavl region "Clinical Hospital of Emergency Care n.a. Solovyev"

    Yaroslavl, Yaroslavsakaya Oblast, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.